TCGA-3C-AALK-01A-11R-A41B-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 48
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.520
- ESTROGEN_RESPONSE_EARLY+0.400
- CHOLESTEROL_HOMEOSTASIS+0.380
- APICAL_JUNCTION+0.350
- ESTROGEN_RESPONSE_LATE+0.350
- COAGULATION+0.310
- TNFA_SIGNALING_VIA_NFKB+0.280
- ANGIOGENESIS+0.260
- MYOGENESIS+0.250
- P53_PATHWAY+0.250
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.480
- E2F_TARGETS-0.440
- OXIDATIVE_PHOSPHORYLATION-0.370
- PROTEIN_SECRETION-0.360
- G2M_CHECKPOINT-0.350
- MYC_TARGETS_V1-0.310
- INTERFERON_GAMMA_RESPONSE-0.300
- HEME_METABOLISM-0.290
- MTORC1_SIGNALING-0.290
- MITOTIC_SPINDLE-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 69d9a82b-5c37-45bd-a1cf-ffe1392e84fc | — | — | 0.874 |
| 2 | 3843de1d-0eaa-48af-be58-903fcf2e5f89 | — | — | 0.857 |
| 3 | SRR13780250 | — | cohortSQ1 | 0.850 |
| 4 | 57583139-d2d3-4b97-a616-aa96058d4682 | — | — | 0.843 |
| 5 | TCGA-OL-A6VQ-01A-12R-A41B-07 | — | A | 0.842 |
| 6 | MBCProject_3632_T1_RNA | — | B | 0.841 |
| 7 | SRR493947 | — | cohortA1 | 0.827 |
| 8 | TCGA-A2-A0CP-01A-11R-A034-07 | — | A | 0.822 |
| 9 | 20020085.TNBC | — | F | 0.820 |
| 10 | TCGA-AC-A23G-01A-11R-A213-07 | — | A | 0.813 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.520 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.400 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.380 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.350 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.350 | Idelalisib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.280 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.260 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.250 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.250 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.250 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.230 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.230 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.220 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.160 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.140 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.130 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.130 | Inavolisib | — uncovered |
| APOPTOSIS | 0.110 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |